The use of oral edaravone for a total of 144 weeks is safe and well-tolerated among patients with amyotrophic lateral ...

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the ...

Amyotrophic_Lateral_Sclerosis_Market_ MRFR reveals steady growth in the ALS market, projecting an increase from $0.94 billion in 2023 to $1 ...

A rare mutation that leads to high CREB3 activity is associated with a reduced risk of developing ALS and slower disease ...

Amylyx (AMLX) announced that the first participant has been dosed in LUMINA, the company’s Phase 1, multinational, randomized, double-blind, ...

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

Scientists at Johns Hopkins Medicine say they have discovered how a group of proteins linked to Parkinson's disease and ...

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves ...

The Ohio House Insurance Committee will hear proponent testimony on HB 24, a bill that would expand Medigap coverage to patients under 65, on Tuesday afternoon.

TRE-515, a small molecule inhibitor of deoxycytidine kinase, is being developed for autoimmune diseases and in clinical ...

MediciNova (MNOV) announced enrollment of the first patient in the NIH-funded Expanded Access Program trial to evaluate MN-166 in patients with ...